Indivior (INDV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Voting matters and shareholder proposals
Election of eight directors is proposed, with all nominees recommended for approval by the board.
Advisory vote on executive compensation is included, with board recommending approval.
Advisory vote on the preferred frequency of future say-on-pay votes is presented, with 'Year' as the recommended option.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026 is proposed.
Other business may be addressed as appropriate during the meeting or any adjournment.
Board of directors and corporate governance
Eight director nominees are listed for election at the annual meeting.
Executive compensation and say-on-pay
Advisory vote on named executive officer compensation is scheduled.
Shareholders are asked to indicate preferred frequency for future say-on-pay votes.
Latest events from Indivior
- Merger forms a $2.2B CNS biopharma leader with strong growth, profitability, and synergies.INDV
Corporate presentation - Merger creates a CNS leader with $2.2B revenue, $888M EBITDA, and $125M in synergies.INDV
Q2 2026 & Merger - SUBLOCADE's growth accelerates with DTC and commercial gains as diversification plans advance.INDV
Jefferies Global Healthcare Conference 2026 - All proposals, including director elections and auditor ratification, were approved.INDV
AGM 2026 - Q1 2026 delivered record EBITDA, 19% revenue growth, and raised guidance on SUBLOCADE strength.INDV
Q1 2026 - Strong financial results, U.S. redomicile, and robust governance mark a pivotal year.INDV
Proxy filing - Record SUBLOCADE growth, margin gains, and a $400M share repurchase program set up further acceleration.INDV
Q4 2025 - SUBLOCADE growth, cost cuts, and organizational overhaul drive the 2025–2026 strategy.INDV
Morgan Stanley 23rd Annual Global Healthcare Conference - SUBLOCADE growth drove FY 2024 gains, but 2025 faces a 17% revenue decline from SUBOXONE Film erosion.INDV
Q4 2024